Pathogenic role of Fgf23 in Hyp mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 1, 2006, Pages

  Liu, Shiguang ^a,c   Zhou, Jianping ^a   Tang, Wen ^a   Jiang, Xi ^b   Rowe, David W ^b   Quarles, L Darryl ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c MS 3018 ^*  (United States)

Author keywords

Fibroblastic growth factor 23; Hypophosphatemia; Osteomalacia; X linked hypophosphatemia

Indexed keywords

CALCITRIOL; CD31 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; FIBROBLAST GROWTH FACTOR 23;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HYPOPHOSPHATEMIA; MALE; MINERALIZATION; MOUSE; NONHUMAN; OSTEOCYTE; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; VITAMIN D RESISTANT RICKETS;

ANIMALS; BODY WEIGHT; BONE DENSITY; BONE MARROW CELLS; CALCIUM; CHOLECALCIFEROL; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HYPOPHOSPHATEMIA, FAMILIAL; MALE; MEMBRANE GLYCOPROTEINS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; OSTEOCYTES; PARATHYROID HORMONE; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHORUS; PROMOTER REGIONS (GENETICS);

EID: 33745850756     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00008.2006     Document Type: Article

References (38)

1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000.
2. 1a. Aono Y, Shimada T, Uamazaki Y, Hino R, Takeuchi Y, Fujita T, Fukumoto S, Nagano N, Wada M, and Yamashita T. The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice (Abstract). J Bone Miner Res 18: S16, 2003.
3. Bai X, Miao D, Li J, Goltzman D, and Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279, 2004.
4. Bai XY, Miao D, Goltzman D, and Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278: 9843-9849, 2003.
5. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, and Tenenhouse HS. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99: 1200-1209, 1997.
6. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, and Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35: 455-462, 2004.
7. Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, and Ecarot B. cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36: 22-28, 1996.
8. Ecarot B, Glorieux FH, Desbarats M, Travers R, and Labelle L. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J Bone Miner Res 7: 215-220, 1992.
9. Econs MJ and Drezner MK. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med 330: 1679-1681, 1994.
10. Fukumoto S and Yamashita T. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11: 385-389, 2002.
11. Guo R and Quarles LD. Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res 12: 1009-1017, 1997.
12. Jiang X, Kalajzic Z, Maye P, Braut A, Bellizzi J, Mina M, and Rowe DW. Histological analysis of GFP expression in murine bone. J Histochem Cytochem 53: 593-602, 2005.
13. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, and White KE. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146: 3883-3891, 2005.
14. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, and Jonsson KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094, 2004.
15. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, and Quarles LD. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005.
16. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, and Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426, 2003.
17. Liu S, Guo R, Tu Q, and Quarles LD. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277: 3686-3697, 2002.
18. Miao D, Bai X, Panda D, McKee M, Karaplis A, and Goltzman D. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology 142: 926-939, 2001.
19. Miyamura T, Tanaka H, Inoue M, Ichinose Y, and Seino Y. The effects of bone marrow transplantation on X-linked hypophosphatemic mice. J Bone Miner Res 15: 1451-1458, 2000.
20. Murshed M, Harmey D, Millan JL, McKee MD, and Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19: 1093-1104, 2005.
21. Nesbitt T, Fujiwara I, Thomas R, Xiao ZS, Quarles LD, and Drezner MK. Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. J Bone Miner Res 14: 2027-2035, 1999.
22. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112: 642-646, 2003.
23. Ruchon AF, Marcinkiewicz M, Siegfried G, Tenenhouse HS, DesGroseillers L, Crine P, and Boileau G. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem 46: 459-468, 1998.
24. Ruchon AF, Tenenhouse HS, Marcinkiewicz M, Siegfried G, Aubin JE, DesGroseillers L, Crine P, and Boileau G. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J Bone Miner Res 15: 1440-1450, 2000.
25. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, and Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.
26. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, and Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505, 2001.
27. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, and Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314: 409-414, 2004.
28. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, and Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004.
29. Strewler GJ. FGF23, hypophosphatemia, and rickets: has phosphatonin been found? Proc Natl Acad Sci USA 98: 5945-5946, 2001.
30. Strom TM, Francis F, Lorenz B, Boddrich A, Econs MJ, Lehrach H, and Meitinger T. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 6: 165-171, 1997.
31. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11: 130-136, 1995.
32. Turner AJ, Brown CD, Carson JA, and Barnes K. The neprilysin family in health and disease. Adv Exp Med Biol 477: 229-240, 2000.
33. Wang H, Yamamoto R, Tanne K, Aubin JE, Maeda N, and Yoahiko Y. Adenovirus-mediated overexpression of FGF23 suppresses osteoblast development and matrix mineralization in fetal rat calvaria cell cultures (Abstract). J Bone Miner Res 20: S128, 2005.
34. Weber TJ, Liu S, Indridason OS, and Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003.
35. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, and Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086, 2001.
36. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, and Quarles LD. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol Endocrinol Metab 275: E700-E708, 1998.
37. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, and Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002.
38. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, and White KE. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146: 4647-4656, 2005.